German pharmaceutical giant Boehringer Ingelheim is the latest company to sue the U.S. government over Medicare price negotiations under the Inflation Reduction Act. The lawsuit, filed late last week in federal court in Connecticut, contends that the act violates the First, Fifth and Eighth Amendments by taking the company's property without due process and fair compensation, imposing excessive fines and compelling its speech.

Merck, Bristol Myers Squibb, Johnson & Johnson's Janssen, Astellas and PhRMA have filed similar lawsuits. In July, the U.S. Chamber of Commerce filed a motion for a preliminary injunction against the program, claiming it would inflict "irreparable harm" on U.S. businesses and patients.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.